Business Wire

NY-IFF

29.2.2024 22:16:30 CET | Business Wire | Press release

Share
IFF Named Top Company in the U.S. for Gender Equality in 2024

IFF (NYSE: IFF)—a world leader in food and beverage, home and personal care, and health—has been named the top American Company for gender equality and tenth globally by Equileap, a leading organization providing data and insights on gender equality in the corporate sector.

In its seventh annual Gender Equality Global Report & Ranking, Equileap provides a status update on gender equality in the corporate world, evaluating 19 different criteria that range from the gender pay gap and female representation at all corporate levels to parental leave and anti-sexual harassment policies. The research examined 3,795 companies, representing 103 million employees globally, that are listed on a major index or in one of 27 developed markets.

“We’re very proud of this recognition by Equileap—the largest provider of gender data to the investor community—which highlights the progress we’ve made and the deliberate actions we’ve taken to achieve gender equality for IFFers,” said Deb Borg, IFF chief human resources, diversity & inclusion, and communications officer. “This progress belongs to all of us who have imagined a more inclusive future and acted on that inspiration. We believe that embracing the uniqueness of our diverse workforce unleashes innovative possibilities at the intersection of science and creativity.”

“By intentionally considering inclusion in how we make decisions, build programs, implement our talent processes and create policies, we ask ourselves how we are eliminating barriers to access so that fair outcomes can flourish at IFF,” said Erik Fyrwald, IFF CEO. “We know that a more diverse and inclusive IFF benefits our people, customers, industry, and communities.”

IFF’s recognition as the leader in Gender Equality highlights the following progress in 2023:

  • Continued progress against its ESG aspiration of achieving Gender Parity at all levels, reaching 40% of the Executive Leadership Team and 38% of senior leadership in 2023
  • Continued to analyze pay equity; data shows the Company has no statistically significant gender pay gaps.
  • Committed to the Living Wage Pledge and embarked on the journey to ensure all our employees around the world receive a living wage as defined within their country.
  • Continued to pursue equitable representation in Leadership Development programs.
  • Piloted Ignite your Impact, a program designed to help women navigate some of the unique challenges they face in leadership.
  • Launched Mentor@IFF, IFF’s enterprise-wide mentoring program.
  • Launched products through IFF Health that are helping women navigate the symptoms of menopause.
  • Increased spending with women suppliers by 13% in our Supplier Diversity efforts.
  • Supported women in the communities in which we work:
    • In the LMR Serbian platform, IFF supported women's entrepreneurship, providing access to alternative income streams by empowering women to manage their own beehives and make honey to sell to local markets.
    • In the guar program in India, objectives included improving knowledge and support devices for women's empowerment. The project started in 2021, and since then, IFF has provided training to 230+ farmers and community members on the topic of women’s empowerment, highlighting the importance of women’s role in the field. IFF also provided 200 women farmers with farming tools to aid their work.

“While we are proud of this recognition and our progress, we recognize there’s much more to do,” said Borg. “In 2024, we will continue our partnership with EDGE—which has been instrumental in our efforts over the years—to advance equity at IFF. We will undergo EDGE Certification in all countries with 200 or more employees.”

To learn more about IFF’s leading Diversity, Equity and Inclusion efforts, visit here.

Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

© 2024 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240229914819/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bregal Milestone Backs Nethive With Majority Growth Investment and JoyComm Acquisition22.10.2026 10:00:00 CEST | Press release

Partnership to support Nethive’s next phase of growth as a leading cybersecurity services and software platform Bregal Milestone, a leading European software growth private equity firm, today announced a majority growth investment in Nethive S.p.A. (“Nethive” or the “Company”), a leading Italian cybersecurity services and software provider. Alongside its investment in Nethive, Bregal Milestone has also backed Nethive’s acquisition of IT security specialist Joy Comm S.r.l. (“JoyComm”). Founded in 2014 by Alessandro Bellato and Diego Rocco, Nethive has become a trusted cybersecurity partner to blue-chip enterprises, SMEs, and public-sector organizations across Italy. Its platform spans managed security services, professional services and technology resale, helping organizations protect critical infrastructure and networks, strengthen cyber resilience and reduce operational complexity. Nethive combines deep technical expertise with 24/7 monitoring, threat detection and response, risk and

EOS and VOP CZ Sign Memorandum of Understanding to Explore Cooperation on Czech Programmes22.10.2026 09:00:00 CEST | Press release

EOS Defence Systems (EOS) and VOP CZ have signed a Memorandum of Understanding (MoU) at Future Forces Forum in Prague to explore cooperation on wheeled armoured vehicle programmes for the Czech Army and other future defence projects in the Czech Republic and Europe where VOP CZ is involved. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021408045/en/ EOS and VOP CZ sign a Memorandum of Understanding at Future Forces Forum in Prague. Left to right: Martin van de Voorde, Sales Director Europe, EOS; Vlastimil Navrátil, Managing Director, VOP CZ; Pavla Ungrová, Sales Director, VOP CZ; Rear Admiral Richard Caton, Australia’s Military Representative to NATO and the EU; Group Captain Michael Schleeman, Australia’s Defence Attaché; and Matej Pupák, Program Lead, VOP CZ. The agreement brings together EOS' expertise in advanced remote weapon systems (RWS) with VOP CZ's established capabilities in military vehicle integration, produ

Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease22.10.2026 09:00:00 CEST | Press release

Ferreri and Prilenia Therapeutics B.V.today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow. Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life. “The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to bu

IQM Quantum Computers Announces Conference Call to Report Third Quarter 2026 Financial Results on November 5, 202622.10.2026 08:00:00 CEST | Press release

As published previously, IQM Quantum Computers Plc (Nasdaq: IQMX) ("IQM" or the "Company"), a global leader in superconducting quantum computers, will report financial results for the third quarter 2026 on Thursday, November 5, 2026. CEO Dr. Jan Goetz and CFO Jan Kuerschner will host a conference call at 3:00 PM EET / 2:00 PM CET / 8:00 AM EST on the same day followed by a Q&A session with analysts. Conference Call and Webcast A live audio webcast of the conference call will be available to the public through the link below and can be accessed in the News & Events section of IQM's Investor Relations website at https://investors.iqm.tech/. A replay of the call will be available at the same location for one year following the call. Participation in the Q&A during the conference call will require registration using the link below. Date: Thursday, November 5, 2026 Time: 3:00 PM EET / 2:00 PM CET / 8:00 AM EST Webcast Link: https://edge.media-server.com/mmc/p/syqjnhp6To ask questions on the

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance22.10.2026 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of 4.765 billion USD for thefirst nine months of 2026, representing 25.1% year-on-year growth at constant currency1, predominantly driven by volume and complemented by favorable mix. Broad-based double-digit growth across geographies and product categories, reflecting strong execution of Galderma’s proven integrated dermatology strategy, with stand-out performance in Therapeutic Dermatology, across both Nemluvio and the mature portfolio, as well as in Dermatological Skincare and Neuromodulators. Continued market outperformance across all three product categories, with net sales growth year-on-year at constant currency of 13.2% in Injectable Aesthetics, 16.2% in Dermatological Skincare, and 64.4% in Therapeutic Dermatology (with Nemluvio net sales of 735 million USD). Strengthening Ga

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye